Company Immix Biopharma, Inc.

IMMX

US45258H1068

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
2.13 ^USD	+1.43%		-2.74%	-69.22%

18/04	Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year	MT
18/04	Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States	CI

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

Number of employees: 16

Managers	Title	Age	Since
Ilya Rachman CEO	Chief Executive Officer	52	01/12/01
Gabriel Morris DFI	Director of Finance/CFO	38	01/21/01
Graham Ross CTO	Chief Tech/Sci/R&D Officer	64	01/21/01
Nandan Oza PRN	Corporate Officer/Principal	61	01/17/01

Members of the board	Title	Age	Since
Jane Buchan BRD	Director/Board Member	60	01/21/01
Jason Hsu BRD	Director/Board Member	50	01/13/01
Magda Marquet BRD	Director/Board Member	65	01/21/01
Carey Ng BRD	Director/Board Member	45	01/19/01
Helen Adams BRD	Director/Board Member	65	01/21/01
Ilya Rachman CEO	Chief Executive Officer	52	01/12/01
Gabriel Morris DFI	Director of Finance/CFO	38	01/21/01
Yekaterina Chudnovsky BRD	Director/Board Member	39	22/23/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	26,468,783	14,277,691 ( 53.94 %)	72,363 ( 0.2734 %)	53.94 %

Name	Equities	%	Valuation
Jason Hsu 18.72 %	4,778,913	18.72 %	15 M $
Yekaterina Chudnovsky 12.69 %	3,241,076	12.69 %	10 M $
AIGH Capital Management LLC 5.698 %	1,455,000	5.698 %	4 M $
Carey Ng 4.054 %	1,035,221	4.054 %	3 M $
Vladimir Torchilin 3.545 %	905,200	3.545 %	3 M $
Ilya Rachman 3.534 %	902,500	3.534 %	3 M $
Sean Senn 3.525 %	900,000	3.525 %	3 M $
Gabriel Morris 1.264 %	322,819	1.264 %	991 054 $
Vanguard Group, Inc. (Subfiler) 0.6282 %	160,398	0.6282 %	492 422 $
EAM Investors LLC 0.4020 %	102,661	0.4020 %	315 169 $

Immix Biopharma, Inc.

11400 West Olympic Boulevard Suite 200

90064, Los Angeles

http://www.immixbio.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.13 USD

Average target price

14 USD

Spread / Average Target

+557.28%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
IMMIX BIOPHARMA, INC.	-69.22%	56.22M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals